Inventurus Knowledge Solutions Limited has informed the Exchange regarding disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Outcome of the Board Meeting held on May 15, 2025.
IKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Smallcap 250 and 0.2 pts more than its IT Enabled Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Inventurus Knowledge Solutions (IKS), a healthcare technology platform, reported strong audited results for the quarter and year ended March 31, 2025. Consolidated revenue from operations grew about 47% to ₹26,640 million (FY24: ₹18,179 million). Profit after tax (consolidated) rose 31% to ₹4,861 million from ₹3,705 million last year. Basic EPS jumped to ₹29.20 versus ₹22.37. Q4 standalone also showed healthy growth with revenue up 58% to ₹2,904 million. Statutory auditor Price Waterhouse issued an unmodified (clean) opinion on both standalone and consolidated results. The company also appointed M/s Manish Ghia & Associates as Secretarial Auditor for a 5-year term (FY26–FY30), subject to shareholder approval. This is IKS Health's first full-year audited result since its stock exchange listing.
Strong revenue and profit growth, clean audit report, and significant debt reduction (consolidated borrowings fell from ~₹11,934M to ~₹7,550M) are positive signals for shareholders. The results may support a positive stock reaction, though Q4 standalone revenue growth of 58% should be viewed in context of post-listing base effect.